research magnet Research Magnet news Medical News

View research about

Essential mixed cryoglobulinemia Dentist Paediatric Cardiology Autoimmune dysautonomia Pain Medicine Fitness Inclusion body myositis (IBM) Juvenile myositis (JM) Pathology Sarcoma Colorectal Cancer Alopecia areata Pemphigus Vascular Surgery Cleft Lip Gall Bladder Cancer Dementia Dermatomyositis Progesterone dermatitis Transverse myelitis Sports Medicine Medical Charity ADHD Foot & Ankle Orthopaedics Cosmetic Surgery Interstitial cystitis (IC) Brain Tumor Primary Biliary Cholangitis Endocrinology Subacute bacterial endocarditis (SBE) Leukodystrophy Procedural Dermatology Molecular Genetic Pathology Autoimmune retinopathy Heart Failure Coronary Artery Disease Narcolepsy Peripheral neuropathy Malignant Hypertension Implantology Angina Paediatric Dentistry Transplant Heamatology Pure red cell aplasia (PRCA) Castleman disease (CD) Nephrology Autoimmune encephalomyelitis Chronic Lymphocytic Leukaemia Orthopaedic Surgery Bile Duct Cancer Undifferentiated connective tissue disease (UCTD) Dressler’s syndrome Dermatology Hyperlipidaemia Cold agglutinin disease Musculoskeletal Oncology Cardiothoracic Surgery Doctor Optic neuritis Epilepsy Parkinson’s Disease Surgical Oncology Ocular cicatricial pemphigoid Overactive Bladder Devic’s disease (neuromyelitis optica) Anti-GBM/Anti-TBM nephritis Autoimmune myocarditis Polymyalgia rheumatica Lower GI Guillain Barre Syndrome Temporal arteritis/Giant cell arteritis Low Back Pain Lung Cancer Hand Surgery Paediatric Surgery Hypertriglyceridemia Perivenous encephalomyelitis Neuroendocrine Tumors Antiphospholipid syndrome Spinal Cord Injury Upper GI Biochemical Genetics Microbiology Reflex sympathetic dystrophy COVID-19 Henoch-Schonlein purpura (HSP) Chronic inflammatory demyelinating polyneuropathy (CIDP) Polyglandular syndromes type I, II, III Paediatric ICU Maternal & Fetal Medicine Cancer Hypogammalglobulinemia Endovascular surgery Discoid lupus Hip & Knee Osteoarthritis Asthma Rheumatic fever Parry Romberg syndrome Pediatrics Obesity & Bariatrics Pancreatic Cancer Prediabetes Syncope & Collapse Microscopic polyangiitis (MPA) Hospice And Palliative Medicine Urology Behcet’s disease General Medicine / Internal Medicine Granulomatosis with Polyangiitis Spina Bifida Thoracic Surgery Neonatal & Perinatal Medicine Bladder Cancer Hepatology Ophthalmology Podiatrist Traumatic Brain Injury Coronavirus Transplant Hepatology Clinical Pharmacology Autoimmune orchitis Specialist In Training Chronic recurrent multifocal osteomyelitis (CRMO) Occupational & Environmental Medicine Liver Cancer Vaginal Cancer Clinic Ankylosing spondylitis Neurosurgery Schmidt syndrome General Surgery Hidradenitis Suppurativa (HS) (Acne Inversa) Evans syndrome Obstetrics And Gynecology Chiropractor Dermatological Immunology Pulmonology Stem Cell Research Pyoderma gangrenosum Psychiatry Immunology & Allergy Amyloidosis Critical Care Ulcerative colitis (UC) Retroperitoneal fibrosis Autoimmune inner ear disease (AIED) Peripheral Vascular Disease Depression Undersea & Hyperbaric Medicine Mona Vale ED Acute Myeloid Leukaemia Thyroid eye disease (TED) Herpes gestationis or pemphigoid gestationis (PG) Psoriasis Lupus Macular Degeneration Pernicious anemia (PA) Head & Neck Surgery Geriatric Psychiatry Cardiology Pharmacy Reactive Arthritis Melanoma Psychosomatic Medicine Linear IgA disease (LAD) Chronic Kidney Disease Palliative Medicine Bullous pemphigoid Clinical Cytogenetics Mitochondrial Myopathies Chronic Ischaemic Heart Disease Audiologist Congenital heart block Tropical Medicine Adolescent Medicine Otology Neurotology Dermatitis herpetiformis Juvenile diabetes (Type 1 diabetes) Muscular Dystrophy Clinical Paediatric Genetics Moya Moya Disease Prostate Cancer Myelin Oligodendrocyte Glycoprotein Antibody Disorder Churg-Strauss Syndrome Restless legs syndrome (RLS) ENT Paediatric Physician Pregnancy Reproductive Endocrinology & Infertility Vulval Cancer Giant cell myocarditis Alzheimers Autoimmune oophoritis Sympathetic ophthalmia (SO) Benign Hypertension Aerospace Medicine Speech Pathologist Medical Administration Palindromic rheumatism (PR) Atrial Fibrillation Transplant Nuclear Medicine Women's Health Breast Fibromyalgia Meningitis CREST syndrome Takayasu’s arteritis Osteopathy Relapsing polychondritis Kawasaki disease Ligneous conjunctivitis Huntingtons Disease Goodpasture’s syndrome COPD Bowel Cancer Skin Cancer Mooren’s ulcer Pars planitis (peripheral uveitis) Inflammatory Arthritis Primary sclerosing cholangitis Haematology Rural & Remote Agammaglobulinemia Organ Donation Raynaud’s phenomenon Addiction Psychiatry Histopathology Vogt-Koyanagi-Harada Disease Hashimoto’s thyroiditis Radiation Oncology Paediatric Respiratory Baló disease Craniofacial Surgery Anal Cancer Medical Organisation Chiropractice Infectious Disease Clinical Researcher Laboratory Immunology Sexual Health Medicine Addison’s disease Achalasia Vitiligo Scleroderma Eosinophilic esophagitis (EoE) Parsonage-Turner syndrome Rare Disease Craniofacial Microsomia Immune thrombocytopenic purpura (ITP) Lambert-Eaton syndrome Rare Diseases Coeliac disease Neurodevelopmental Disabilities Sleep Medicine Lichen planus Mircobiology Diabetes & Metabolism Burns Cystic Fibrosis Optometry Spinal Surgery Clinical Cardiac Electrophysiology Complementary Medicine Delirium Physiotherapy Emergency Medicine Brain Injury Medicine Hospital Geriatric Medicine Polymyositis Insulin Resistance Fibrosing alveolitis Anesthesiology Neuro Ophthalmology Axonal & neuronal neuropathy (AMAN) MedicalDirector software Testicular Cancer Schizophrenia Mucha-Habermann disease Rheumatology Womb Cancer Clinical Genetics Adult Reconstructive Orthopaedics Gynecologic Oncology Neonatal Lupus Chronic Myeloid Leukaemia Gynaecology Pediatric Allergy & Immunology Paediatric Emergency Medicine Uveitis & Ocular Immunology Hemolytic anemia Internal Medicine Oesophaegal Cancer Forensic Psychiatry Physiotherapist Paediatric Orthopaedics Oncology Cerebral Atherosclerosis Myeloma cleft palate Provider Postpericardiotomy syndrome Penile Cancer Neurology Queer Health Occupational Therapy Cardiothoracic Intensive Care Chinese Medical Practitioner Cerebrovascular & Skull Base Surgery Disaster Medicine Chagas disease Intensive Care Medicine International Health Sleep Apnoea Glomerulonephritis Psychologist Nutrition Graves’ disease TIA Interventional Radiology Acute Lymphoblastic Leukaemia Thyroid Cancer Dietician Crohn’s disease Sports & Exercise Medicine Scleritis Advanced Heart Failure & Transplant Cardiology Orthodontics Adult Still's disease Dentistry Myelodysplasia Cicatricial pemphigoid Paramedicine Cosmetic Medicine Lichen sclerosus Radiology Multiple Sclerosis Neuro Oncology Child And Adolescent Psychiatry Geriatric Wellness Polyarteritis nodosa Phonetics Hypercholesterolaemia Neurodegenerative Disorders Myocardial infarction Kidney Cancer Stiff person syndrome (SPS) Cataracts Neuro Intensive Care Susac’s syndrome Neuromuscular Medicine Leukocytoclastic vasculitis POEMS syndrome Eosinophilic fasciitis Cogan’s syndrome Thrombocytopenic purpura (TTP) Meniere’s disease Ophthalmic Pathology Endovascular Surgical Neuroradiology Optometrist Audiology Sperm & testicular autoimmunity Carotid Artery occlusion Adult Cardiothoracic Anesthesiology Gastroenterology Giant cell arteritis (temporal arteritis) Simulation Medicine Sjögren’s syndrome Stroke Multifocal Motor Neuropathy (MMN) Autoimmune urticaria HIV / AIDS Female Pelvic Medicine & Reconstructive Surgery Respiratory Medicine IgG4-related sclerosing disease Tolosa-Hunt syndrome (THS) Nurse Juvenile arthritis Celiac disease Diabetes Mellitus Mouth, Head and Neck Cancer Pharmacist Sarcoidosis Autoimmune pancreatitis Oral Health Dermatopathology Laryngeal Cancer Lyme disease chronic Autoimmune hepatitis Paraneoplastic cerebellar degeneration (PCD) Interventional Cardiology Technology Podiatry Endoscopy Stomach Cancer Patient Paroxysmal nocturnal hemoglobinuria (PNH) Psychology Benign mucosal pemphigoid Psoriatic arthritis Endometriosis Obstetric Anesthesiology Healthcare Otolaryngology Bariatric Surgery Coxsackie myocarditis Breast Cancer Nuclear Radiology Applied Dermatology Metabolic Syndrome Cervical Cancer Uterine Cancer Eye Cancer Diagnostic Laboratory Immunology Transplant Pulmonology IgA Nephropathy Public Health Rehabilitation Medicine Erythema nodosum Mesothelioma Robotic Surgery Inflammatory Bowel Disease Clinical Immunology General Practice (Family Medicine) Toxicology ATSI Health Practitioner Non Hodgkin Lymphoma Transplant Nephrology Wheel Travel Medicine Neutropenia Public Health Medicine Musculoskeletal Radiology Retrieval Medicine Blood Cancer Ovarian Cancer Addiction Medicine Plastic Surgery Conference Organiser Osteopath Oral & Maxillofacial Surgery Motor Neuron Disease Occupational Therapist Trauma Cerebral Palsy Autoimmune angioedema

The latest medical research on Paediatric Physician

The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about paediatric physician gathered by our medical AI research bot.

The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.

Want more personalised results?

Request Access

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

N Engl J

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain.

In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent. A significant improvement in disease-free survival according to investigator assessment (the primary end point) was shown previously. Overall survival was the key secondary end point. Safety was a secondary end point.

A total of 496 participants were assigned to receive pembrolizumab and 498 to receive placebo. As of September 15, 2023, the median follow-up was 57.2 months. The disease-free survival benefit was consistent with that in previous analyses (hazard ratio for recurrence or death, 0.72; 95% confidence interval [CI], 0.59 to 0.87). A significant improvement in overall survival was observed with pembrolizumab as compared with placebo (hazard ratio for death, 0.62; 95% CI, 0.44 to 0.87; P = 0.005). The estimated overall survival at 48 months was 91.2% in the pembrolizumab group, as compared with 86.0% in the placebo group; the benefit was consistent across key subgroups. Pembrolizumab was associated with a higher incidence of serious adverse events of any cause (20.7%, vs. 11.5% with placebo) and of grade 3 or 4 adverse events related to pembrolizumab or placebo (18.6% vs. 1.2%). No deaths were attributed to pembrolizumab therapy.

Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).

Burden of Childhood Cancer and the Social and Economic Challenges in Adulthood: A Systematic Review and Meta-Analysis.

JAMA Pediatrics

Significant advancements in pediatric oncology have led to a continuously growing population of survivors. Although extensive research is being conducted on the short-, medium-, and long-term somatic effects, reports on psychosocial reintegration are often conflicting; therefore, there is an urgent need to synthesize the evidence to obtain the clearest understanding and the most comprehensive answer.

To provide a comprehensive review and analysis of the socioeconomic attainment of childhood cancer survivors (CCSs) compared with their unaffected peers.

A systematic review and meta-analysis was conducted using data obtained from a comprehensive search of MEDLINE (via PubMed), Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) databases on October 23, 2021; the search was updated until July 31, 2023.

Eligible articles reported on educational attainment, employment, family formation, quality of life (QoL), or health-risk behavior-related outcomes of CCSs, and compared them with their unaffected peers. Study selection was performed in duplicate by 4 blinded independent coauthors.

Data extraction was performed in duplicate by 4 independent authors following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Outcome measures were odds ratios (ORs) and mean differences with 95% CIs; data were pooled using a random-effects model.

The search identified 43 913 articles, 280 of which were eligible for analysis, reporting data on a total of 389 502 survivors. CCSs were less likely to complete higher levels of education (OR, 0.69; 95% CI, 0.40-1.18), had higher odds of health-related unemployment (OR, 2.94; 95% CI, 1.90-4.57), and showed lower rates of marriage (OR, 0.72; 95% CI, 0.63-0.84) and parenthood (OR, 0.60; 95% CI, 0.49-0.74) compared with population-based controls.

Study findings suggest that CCSs face several socioeconomic difficulties; as a result, the next goal of pediatric oncology should be to minimize adverse effects, as well as to provide lifelong survivorship support aimed at maximizing social reintegration.

Influence of Eat, Sleep, and Console on Infants Pharmacologically Treated for Opioid Withdrawal: A Post Hoc Subgroup Analysis of the ESC-NOW Randomized Clinical Trial.

JAMA Pediatrics

The function-based eat, sleep, console (ESC) care approach substantially reduces the proportion of infants who receive pharmacologic treatment for neonatal opioid withdrawal syndrome (NOWS). This reduction has led to concerns for increased postnatal opioid exposure in infants who receive pharmacologic treatment. However, the effect of the ESC care approach on hospital outcomes for infants pharmacologically treated for NOWS is currently unknown.

To evaluate differences in opioid exposure and total length of hospital stay (LOS) for pharmacologically treated infants managed with the ESC care approach vs usual care with the Finnegan tool.

This post hoc subgroup analysis involved infants pharmacologically treated in ESC-NOW, a stepped-wedge cluster randomized clinical trial conducted at 26 US hospitals. Hospitals maintained pretrial practices for pharmacologic treatment, including opioid type, scheduled opioid dosing, and use of adjuvant medications. Infants were born at 36 weeks' gestation or later, had evidence of antenatal opioid exposure, and received opioid treatment for NOWS between September 2020 and March 2022. Data were analyzed from November 2022 to January 2024.

Opioid treatment for NOWS and the ESC care approach.

For each outcome (total opioid exposure, peak opioid dose, time from birth to initiation of first opioid dose, length of opioid treatment, and LOS), we used generalized linear mixed models to adjust for the stepped-wedge design and maternal and infant characteristics.

In the ESC-NOW trial, 463 of 1305 infants were pharmacologically treated (143/603 [23.7%] in the ESC care approach group and 320/702 [45.6%] in the usual care group). Mean total opioid exposure was lower in the ESC care approach group with an absolute difference of 4.1 morphine milligram equivalents per kilogram (MME/kg) (95% CI, 1.3-7.0) when compared with usual care (4.8 MME/kg vs 8.9 MME/kg, respectively; P = .001). Mean time from birth to initiation of pharmacologic treatment was 22.4 hours (95% CI, 7.1-37.7) longer with the ESC care approach vs usual care (75.4 vs 53.0 hours, respectively; P = .002). No significant difference in mean peak opioid dose was observed between groups (ESC care approach, 0.147 MME/kg, vs usual care, 0.126 MME/kg). The mean length of treatment was 6.3 days shorter (95% CI, 3.0-9.6) in the ESC care approach group vs usual care group (11.8 vs 18.1 days, respectively; P < .001), and mean LOS was 6.2 days shorter (95% CI, 3.0-9.4) with the ESC care approach than with usual care (16.7 vs 22.9 days, respectively; P < .001).

When compared with usual care, the ESC care approach was associated with less opioid exposure and shorter LOS for infants pharmacologically treated for NOWS. The ESC care approach was not associated with a higher peak opioid dose, although pharmacologic treatment was typically initiated later.

ClinicalTrials.gov Identifier: NCT04057820.

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.

N Engl J

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited statistical power, uncertain nodal radiotherapy target volumes, and a scarcity of data on relevant clinical subgroups.

We conducted a noninferiority trial in which patients with clinically node-negative primary T1 to T3 breast cancer (tumor size, T1, ≤20 mm; T2, 21 to 50 mm; and T3, >50 mm in the largest dimension) with one or two sentinel-node macrometastases (metastasis size, >2 mm in the largest dimension) were randomly assigned in a 1:1 ratio to completion axillary-lymph-node dissection or its omission (sentinel-node biopsy only). Adjuvant treatment and radiation therapy were used in accordance with national guidelines. The primary end point was overall survival. We report here the per-protocol and modified intention-to-treat analyses of the prespecified secondary end point of recurrence-free survival. To show noninferiority of sentinel-node biopsy only, the upper boundary of the confidence interval for the hazard ratio for recurrence or death had to be below 1.44.

Between January 2015 and December 2021, a total of 2766 patients were enrolled across five countries. The per-protocol population included 2540 patients, of whom 1335 were assigned to undergo sentinel-node biopsy only and 1205 to undergo completion axillary-lymph-node dissection (dissection group). Radiation therapy including nodal target volumes was administered to 1192 of 1326 patients (89.9%) in the sentinel-node biopsy-only group and to 1058 of 1197 (88.4%) in the dissection group. The median follow-up was 46.8 months (range, 1.5 to 94.5). Overall, 191 patients had recurrence or died. The estimated 5-year recurrence-free survival was 89.7% (95% confidence interval [CI], 87.5 to 91.9) in the sentinel-node biopsy-only group and 88.7% (95% CI, 86.3 to 91.1) in the dissection group, with a country-adjusted hazard ratio for recurrence or death of 0.89 (95% CI, 0.66 to 1.19), which was significantly (P<0.001) below the prespecified noninferiority margin.

The omission of completion axillary-lymph-node dissection was noninferior to the more extensive surgery in patients with clinically node-negative breast cancer who had sentinel-node macrometastases, most of whom received nodal radiation therapy. (Funded by the Swedish Research Council and others; SENOMAC ClinicalTrials.gov number, NCT02240472.).

Trial of Lixisenatide in Early Parkinson's Disease.

N Engl J

Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.

In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.

A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.

In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.

N Engl J

Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for severe Covid-19 or who are fully vaccinated and have at least one risk factor for severe Covid-19 has not been established.

In this phase 2-3 trial, we randomly assigned adults who had confirmed Covid-19 with symptom onset within the past 5 days in a 1:1 ratio to receive nirmatrelvir-ritonavir or placebo every 12 hours for 5 days. Patients who were fully vaccinated against Covid-19 and who had at least one risk factor for severe disease, as well as patients without such risk factors who had never been vaccinated against Covid-19 or had not been vaccinated within the previous year, were eligible for participation. Participants logged the presence and severity of prespecified Covid-19 signs and symptoms daily from day 1 through day 28. The primary end point was the time to sustained alleviation of all targeted Covid-19 signs and symptoms. Covid-19-related hospitalization and death from any cause were also assessed through day 28.

Among the 1296 participants who underwent randomization and were included in the full analysis population, 1288 received at least one dose of nirmatrelvir-ritonavir (654 participants) or placebo (634 participants) and had at least one postbaseline visit. The median time to sustained alleviation of all targeted signs and symptoms of Covid-19 was 12 days in the nirmatrelvir-ritonavir group and 13 days in the placebo group (P = 0.60). Five participants (0.8%) in the nirmatrelvir-ritonavir group and 10 (1.6%) in the placebo group were hospitalized for Covid-19 or died from any cause (difference, -0.8 percentage points; 95% confidence interval, -2.0 to 0.4). The percentages of participants with adverse events were similar in the two groups (25.8% with nirmatrelvir-ritonavir and 24.1% with placebo). In the nirmatrelvir-ritonavir group, the most commonly reported treatment-related adverse events were dysgeusia (in 5.8% of the participants) and diarrhea (in 2.1%).

The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir-ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials.gov number, NCT05011513.).

Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.

N Engl J

Despite the availability of effective therapies for patients with chronic kidney disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad), the results of large-scale trials examining the implementation of guideline-directed therapy to reduce the risk of death and complications in this population are lacking.

In this open-label, cluster-randomized trial, we assigned 11,182 patients with the kidney-dysfunction triad who were being treated at 141 primary care clinics either to receive an intervention that used a personalized algorithm (based on the patient's electronic health record [EHR]) to identify patients and practice facilitators to assist providers in delivering guideline-based interventions or to receive usual care. The primary outcome was hospitalization for any cause at 1 year. Secondary outcomes included emergency department visits, readmissions, cardiovascular events, dialysis, and death.

We assigned 71 practices (enrolling 5690 patients) to the intervention group and 70 practices (enrolling 5492 patients) to the usual-care group. The hospitalization rate at 1 year was 20.7% (95% confidence interval [CI], 19.7 to 21.8) in the intervention group and 21.1% (95% CI, 20.1 to 22.2) in the usual-care group (between-group difference, 0.4 percentage points; P = 0.58). The risks of emergency department visits, readmissions, cardiovascular events, dialysis, or death from any cause were similar in the two groups. The risk of adverse events was also similar in the trial groups, except for acute kidney injury, which was observed in more patients in the intervention group (12.7% vs. 11.3%).

In this pragmatic trial involving patients with the triad of chronic kidney disease, type 2 diabetes, and hypertension, the use of an EHR-based algorithm and practice facilitators embedded in primary care clinics did not translate into reduced hospitalization at 1 year. (Funded by the National Institutes of Health and others; ICD-Pieces ClinicalTrials.gov number, NCT02587936.).

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J

Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK-positive NSCLC are lacking.

We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK-positive NSCLC of stage IB (tumors ≥4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was disease-free survival, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat population. Other end points included central nervous system (CNS) disease-free survival, overall survival, and safety.

In total, 257 patients were randomly assigned to receive alectinib (130 patients) or chemotherapy (127 patients). The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001) and 93.6% and 63.7%, respectively, in the intention-to-treat population (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001). Alectinib was associated with a clinically meaningful benefit with respect to CNS disease-free survival as compared with chemotherapy (hazard ratio for CNS disease recurrence or death, 0.22; 95% CI, 0.08 to 0.58). Data for overall survival were immature. No unexpected safety findings were observed.

Among patients with resected ALK-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).

Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage.

N Engl J

Trials of surgical evacuation of supratentorial intracerebral hemorrhages have generally shown no functional benefit. Whether early minimally invasive surgical removal would result in better outcomes than medical management is not known.

In this multicenter, randomized trial involving patients with an acute intracerebral hemorrhage, we assessed surgical removal of the hematoma as compared with medical management. Patients who had a lobar or anterior basal ganglia hemorrhage with a hematoma volume of 30 to 80 ml were assigned, in a 1:1 ratio, within 24 hours after the time that they were last known to be well, to minimally invasive surgical removal of the hematoma plus guideline-based medical management (surgery group) or to guideline-based medical management alone (control group). The primary efficacy end point was the mean score on the utility-weighted modified Rankin scale (range, 0 to 1, with higher scores indicating better outcomes, according to patients' assessment) at 180 days, with a prespecified threshold for posterior probability of superiority of 0.975 or higher. The trial included rules for adaptation of enrollment criteria on the basis of hemorrhage location. A primary safety end point was death within 30 days after enrollment.

A total of 300 patients were enrolled, of whom 30.7% had anterior basal ganglia hemorrhages and 69.3% had lobar hemorrhages. After 175 patients had been enrolled, an adaptation rule was triggered, and only persons with lobar hemorrhages were enrolled. The mean score on the utility-weighted modified Rankin scale at 180 days was 0.458 in the surgery group and 0.374 in the control group (difference, 0.084; 95% Bayesian credible interval, 0.005 to 0.163; posterior probability of superiority of surgery, 0.981). The mean between-group difference was 0.127 (95% Bayesian credible interval, 0.035 to 0.219) among patients with lobar hemorrhages and -0.013 (95% Bayesian credible interval, -0.147 to 0.116) among those with anterior basal ganglia hemorrhages. The percentage of patients who had died by 30 days was 9.3% in the surgery group and 18.0% in the control group. Five patients (3.3%) in the surgery group had postoperative rebleeding and neurologic deterioration.

Among patients in whom surgery could be performed within 24 hours after an acute intracerebral hemorrhage, minimally invasive hematoma evacuation resulted in better functional outcomes at 180 days than those with guideline-based medical management. The effect of surgery appeared to be attributable to intervention for lobar hemorrhages. (Funded by Nico; ENRICH ClinicalTrials.gov number, NCT02880878.).

FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.

N Engl J

The benefit of fractional flow reserve (FFR)-guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear.

In this multinational, registry-based, randomized trial, we assigned patients with STEMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing primary percutaneous coronary intervention (PCI) of the culprit lesion to receive either FFR-guided complete revascularization of nonculprit lesions or no further revascularization. The primary outcome was a composite of death from any cause, myocardial infarction, or unplanned revascularization. The two key secondary outcomes were a composite of death from any cause or myocardial infarction and unplanned revascularization.

A total of 1542 patients underwent randomization, with 764 assigned to receive FFR-guided complete revascularization and 778 assigned to receive culprit-lesion-only PCI. At a median follow-up of 4.8 years (interquartile range, 4.3 to 5.2), a primary-outcome event had occurred in 145 patients (19.0%) in the complete-revascularization group and in 159 patients (20.4%) in the culprit-lesion-only group (hazard ratio, 0.93; 95% confidence interval [CI], 0.74 to 1.17; P = 0.53). With respect to the secondary outcomes, no apparent between-group differences were observed in the composite of death from any cause or myocardial infarction (hazard ratio, 1.12; 95% CI, 0.87 to 1.44) or unplanned revascularization (hazard ratio, 0.76; 95% CI, 0.56 to 1.04). There were no apparent between-group differences in safety outcomes.

Among patients with STEMI or very-high-risk NSTEMI and multivessel coronary artery disease, FFR-guided complete revascularization was not shown to result in a lower risk of a composite of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only PCI at 4.8 years. (Funded by the Swedish Research Council and others; FULL REVASC ClinicalTrials.gov number, NCT02862119.).

Transcatheter or Surgical Treatment of Aortic-Valve Stenosis.

N Engl J

Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice.

In this randomized noninferiority trial conducted at 38 sites in Germany, we assigned patients with severe aortic stenosis who were at low or intermediate surgical risk to undergo either TAVI or SAVR. Percutaneous- and surgical-valve prostheses were selected according to operator discretion. The primary outcome was a composite of death from any cause or fatal or nonfatal stroke at 1 year.

A total of 1414 patients underwent randomization (701 to the TAVI group and 713 to the SAVR group). The mean (±SD) age of the patients was 74±4 years; 57% were men, and the median Society of Thoracic Surgeons risk score was 1.8% (low surgical risk). The Kaplan-Meier estimate of the primary outcome at 1 year was 5.4% in the TAVI group and 10.0% in the SAVR group (hazard ratio for death or stroke, 0.53; 95% confidence interval [CI], 0.35 to 0.79; P<0.001 for noninferiority). The incidence of death from any cause was 2.6% in the TAVI group and 6.2% in the SAVR group (hazard ratio, 0.43; 95% CI, 0.24 to 0.73); the incidence of stroke was 2.9% and 4.7%, respectively (hazard ratio, 0.61; 95% CI, 0.35 to 1.06). Procedural complications occurred in 1.5% and 1.0% of patients in the TAVI and SAVR groups, respectively.

Among patients with severe aortic stenosis at low or intermediate surgical risk, TAVI was noninferior to SAVR with respect to death from any cause or stroke at 1 year. (Funded by the German Center for Cardiovascular Research and the German Heart Foundation; DEDICATE-DZHK6 ClinicalTrials.gov number, NCT03112980.).

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

N Engl J

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.

We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level.

A total of 616 participants underwent randomization. The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001). The results for the confirmatory secondary end points favored semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]; win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]; and estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]). Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.

Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).